Crown Bioscience Acquires Molecular Response’s Patient Derived Xenograft (PDX) Business

18-Feb-2015 - USA

Crown Bioscience, Inc. has announced the acquisition of Molecular Response’s PDX models and PDX service operations. The acquisition reinforces Crown’s on-going strategy to be the leading global provider of Translational oncology services with facilities in Asia, the USA and Europe.

Crown is acquiring all of Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development from Molecular Response’s viable tumor bank of over 140,000 unique cryopreserved 100% U.S. tumor samples, with the ability to further select and develop models from the wider collection. The majority of these tissues come from patients who have received prior treatment, many from metastatic tumors. Each tumor is supported by a companion molecular biobank and a suite of curated patient and sample data; the collection representing over 76 clinical diagnoses.

With the Molecular Response PDX library acquisition and further commitment to develop thousands of additional unique PDX models from the viable tumor bank, the Crown collection will be the world’s largest and most comprehensive collection of patient derived models both clinically and ethnically diverse, deriving tumor models from Asia, the USA, and Europe. These models include multiple stages of cancer development, across a wide range of cancer types and are representative of both patients that are treatment naïve as well as those who have received prior treatment. This truly unique asset provides a 360 degree view of patient relevant disease to support the oncology drug discovery process.

The Molecular Response facilities and personnel in San Diego will be designated as a global center of excellence for Translational Oncology, and will complement Crown’s existing operations in Beijing, Shanghai, Kannapolis, North Carolina and the UK, providing local expertise and support to Crown’s global clients.

https://www.bionity.com/en/news/151712/crown-bioscience-acquires-molecular-responses-patient-derived-xenograft-pdx-business.html